Go to deals
Healthcare

Open Orphan has successfully raised capital in an oversubscribed fundraise

May 2020 — Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.

Our role in the transaction

Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.

Talk to the deal team

Geoff Nash

Director
London, United Kingdom
Oaklins Cavendish

Related deals

Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Private Equity | Consumer & Retail

Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild

Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.

Learn more
Veremark has completed a secondary share sale
Business Support Services

Veremark has completed a secondary share sale

Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.

Learn more
Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Food & Beverage

Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi

Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.

Learn more